Chandra Panchal obtained a B.Sc. (1972) and a M.Sc., in Molecular Biology (1974) from the University of Toronto, and a Ph.D., in Biochemical Engineering from the University of Western Ontario (1979).
Dr. Panchal is presently President & CEO at Axcelon Biopolymers Corporation, of London, Ontario, and Managing Director of Panford Investment Corp of Montreal. From 1989-1999 he was Co-founder, President, and CEO of Procyon Biopharma Inc., and from1999-2006 he was Chief Scientific Officer and Senior Executive VP. From 2006 to 2008 he was Executive VP, Business Development, Licensing & Intellectual Property, at Ambrilia Biopharma Inc., which was a merger between Procyon and Cellpep Inc., of France. Prior to co-founding Procyon, Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentation and product development at John Labatt Ltd., a multinational food and beverage company.
Dr. Panchal has authored over 50 scientific papers and has edited a book entitled Yeast Strain Selection, published in 1990. Dr. Panchal has been on the editorial board of the Canadian Journal of Microbiology and is a co-inventor in respect of several patents in oncology, diagnostics and industrial microbiology. Dr. Panchal is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. He currently sits on the Boards of: Chemaphor (TSX.V: CFR), Canadian Oil Recovery and Remediation Inc.,(CORRE; TSX.V:CVR), Cardiogenics Inc.,(NASDAQ BB:CGNH.OB) Rodocanachi Capital Pool Company (TSX.V.ROD.P), and MaRS Innovation.
